Reviva Pharmaceuticals Prices $10M Public Offering

Got story updates? Submit your updates here. ›

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) announced the pricing of a $10 million public offering with healthcare-focused institutional investors. The company will sell 6,666,667 shares of common stock (or equivalents) along with Series G and Series H warrants to purchase additional shares. The offering is expected to close on or around March 20, 2026, subject to customary closing conditions.

Why it matters

This capital raise will help fund Reviva's ongoing research and development efforts, including a planned Phase 3 trial for its lead drug candidate brilaroxazine in schizophrenia. As a late-stage pharmaceutical company, securing funding is crucial for Reviva to advance its pipeline of therapies targeting central nervous system, inflammatory, and cardiometabolic diseases.

The details

Under the terms of the offering, Reviva will sell the shares and warrants at a combined price of $1.50 per unit. The Series G Warrants will have an exercise price of $1.50 per share and expire in 5 years, while the Series H Warrants will also have a $1.50 exercise price but expire in 12 months. A.G.P./Alliance Global Partners is acting as the sole placement agent for the transaction.

• The offering is expected to close on or around March 20, 2026.
• The Series G Warrants will be exercisable immediately and expire 5 years from the issuance date.
• The Series H Warrants will be exercisable immediately and expire 12 months from the issuance date.

What’s next

The offering is expected to close on or around March 20, 2026, subject to the satisfaction of customary closing conditions.